Armata Pharmaceuticals (NYSE: ARMP) advances AP-SA02 toward Phase 3 with $28.7M DoD backing
Rhea-AI Filing Summary
Armata Pharmaceuticals, Inc. reported major progress advancing AP-SA02, its intravenously administered multi-phage therapy for complicated Staphylococcus aureus bacteremia, toward a planned Phase 3 superiority study intended to support a future Biologics License Application.
Armata highlighted submission of the complete Phase 3 protocol and comprehensive responses to all FDA End-of-Phase 2 comments, completion of four AP-SA02 engineering manufacturing runs, and plans to initiate the pivotal Phase 3 trial in the second half of 2026. The company also noted an additional $2.5 million continuation award from the U.S. Department of Defense, bringing total funding under that award to $28.7 million to support Phase 3 readiness, and announced the promotion of David House to Chief Financial Officer.
Positive
- None.
Negative
- None.
Filing Explained
As of March 31, Armata had $4.754 million cash—74 days of quarterly operating cash use—while July 20 funding for Phase 3 execution remained unresolved.
On
At
The disclosure therefore establishes progress toward the planned study but not its completion or full execution funding, leaving the program’s next financing milestone unresolved.
The named watch points are whether the study begins in the planned second half of 2026 and whether the company identifies funding for execution beyond the award’s readiness activities.
Sources and calculations
- Armata Pharmaceuticals Form 8-K (2026-07-20)
- Armata Pharmaceuticals first-quarter 2026 fundamentals (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $4,754,000 / ($5,782,000 / 90) = [object Object]
8-K Event Classification
Key Figures
Key Terms
Phase 3 superiority study medical
Biologics License Application regulatory
Qualified Infectious Disease Product regulatory
current Good Manufacturing Practices technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What clinical progress did Armata Pharmaceuticals (ARMP) report for AP-SA02?
How much Department of Defense funding has Armata Pharmaceuticals (ARMP) received?
When does Armata Pharmaceuticals (ARMP) plan to start the Phase 3 study of AP-SA02?
What leadership change did Armata Pharmaceuticals (ARMP) announce?
What regulatory designations has AP-SA02 received according to Armata Pharmaceuticals (ARMP)?
What earlier clinical data support Armata Pharmaceuticals’ (ARMP) AP-SA02 program?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (IRS Employer Identification No.) |
| | |||
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
| Item 7.01 | Regulation FD Disclosure. |
On July 20, 2026, Armata Pharmaceuticals, Inc. (the “Company”) issued a press release announcing significant clinical, regulatory, manufacturing and operational progress supporting advancement of AP-SA02, the Company’s intravenously administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate, toward a planned Phase 3 superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (“MSSA”) or methicillin-resistant S. aureus (“MRSA”).
The press release further discussed a $2.5 million award announced on June 23, 2026 from the U.S. Department of Defense, which is a continuation of a previously announced award and brings total funding received to date under that award to $28.7 million. These additional $2.5 million funds are intended to support activities related to the Company’s continued preparation and readiness for its planned Phase 3 clinical study. The Company is in close communication with its partners at the DoD regarding potential new support, including for the execution of the planned Phase 3 clinical study. Separate from this existing DoD award, or any potential new DoD award, the Company also continues to pursue and evaluate other funding pathways to support execution of the planned Phase 3 clinical study.
The press release further provided a corporate update, including the promotion of David House to Chief Financial Officer.
The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated July 20, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 20, 2026 | Armata Pharmaceuticals, Inc. | |
| By: | /s/ David House | |
| Name: | David House | |
| Title: | Chief Financial Officer | |
- 3 -
Exhibit 99.1
Armata Pharmaceuticals Achieves Key Progress
Across Clinical, Regulatory and Manufacturing Activities
Supporting Planned Phase 3 Initiation of AP-SA02
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting
Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step
Phase 3 superiority study remains on track to initiate in the second half of 2026
LOS ANGELES, Calif., July 20, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing and operational progress supporting advancement of AP-SA02, the Company’s intravenously administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate, toward a planned Phase 3 superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (“MSSA”) or methicillin-resistant S. aureus (“MRSA”).
Recent milestones include submission of the complete Phase 3 protocol and comprehensive responses to all comments received from the U.S. Food and Drug Administration (“FDA”) following the Company’s End-of-Phase 2 (EOP2) meeting, and completion of key manufacturing activities supporting Phase 3 readiness. Collectively, these milestones support the Company’s planned initiation of its pivotal Phase 3 superiority study in the second half of 2026, designed to support a future Biologics License Application (“BLA”) for AP-SA02.
Recent Regulatory and Operational Progress
| · | Submitted the complete Phase 3 superiority protocol to the FDA for AP-SA02, incorporating all comments received in the End-of-Phase 2 (“EOP2”) meeting written response. |
| · | Submitted complete responses to all FDA comments on clinical, Chemistry, Manufacturing, and Controls, (“CMC”) and regulatory topics raised in the EOP2 meeting written response. |
| · | Completed four engineering runs of AP-SA02 at the Company’s in-house cGMP manufacturing facility in Los Angeles, CA. Production of clinical trial material to support the planned Phase 3 clinical study is the next planned manufacturing step. |
Department of Defense (DoD) Award
The $2.5 million announced on June 23, 2026 is a continuation of the previously announced award from the U.S. Department of Defense (“DoD”) i bringing total funding received to date under this award to $28.7 million. These additional $2.5 million funds are intended to support activities related to Armata’s continued preparation and readiness for its planned Phase 3 clinical study. The Company is in close communication with its partners at the DoD regarding potential new support, including for the execution of the planned Phase 3 clinical study.
Separate from the existing or any new DoD award, the Company continues to pursue and evaluate other funding pathways to support the execution of the planned Phase 3 clinical study.
“Advancing AP-SA02 into a Phase 3 superiority study in complicated S. aureus bacteremia remains our top priority,” said Dr. Deborah Birx, Chief Executive Officer of Armata. “These submissions move us closer to that goal, and we are focused on initiating a rigorously designed and operationally efficient study to support a future Biologics License Application and potential registration.”
Executive Leadership Update
Armata also announced the promotion of David House to Chief Financial Officer. Mr. House has served as the Company’s Senior Vice President, Finance and Principal Financial Officer since August 2024. The appointment ensures Armata has the right financial leadership in place to execute on its strategy and advance its clinical programs through late-stage development.
i Department of Defense (DoD) award received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.
About AP-SA02
Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received Qualified Infectious Disease Product (QIDP), and Fast Track designations from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy (“BAT”) compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to initiate in the second half of 2026.
About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.
Forward Looking Statements
This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; Armata’s planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”), including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569